PT - JOURNAL ARTICLE AU - Katsumata, Yoshinori AU - Muramoto, Yuki AU - Ishida, Noriyuki AU - Takemura, Ryo AU - Nagashima, Kengo AU - Ikoma, Takenori AU - Kawamatsu, Naoto AU - Araki, Masaru AU - Goda, Ayumi AU - Okawara, Hiroki AU - Sawada, Tomonori AU - Kawakubo Ichihara, Yumiko AU - Hattori, Osamu AU - Yamaoka, Koki AU - Seki, Yuta AU - Ryuzaki, Toshinobu AU - Ikura, Hidehiko AU - Nakashima, Daisuke AU - Nagura, Takeo AU - Nakamura, Masaya AU - Sato, Kazuki AU - Shiraishi, Yasuyuki TI - Sweat lactate sensor for detecting anaerobic threshold in heart failure: a prospective clinical trial (LacS-001) AID - 10.1101/2023.08.15.23294144 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.15.23294144 4099 - http://medrxiv.org/content/early/2023/08/17/2023.08.15.23294144.short 4100 - http://medrxiv.org/content/early/2023/08/17/2023.08.15.23294144.full AB - Background The ventilatory threshold (VT), which requires an expensive analyzer and expertise in assessment, has not been widely and conveniently used in a clinical setting. This prospective clinical trial (LacS-001) aimed to investigate the safety of a lactate-monitoring sweat sensor, and the correlation between the lactate threshold in sweat (sLT) and the VT, to establish a simple method for determining the anaerobic threshold in patients with heart failure (HF).Methods We recruited 50 patients with HF and New York Heart Association functional classification I–II, with a median age of 63.5 years (interquartile range: 58.0–72.0 years). Incremental exercise tests were conducted, and changes in sweat lactate levels were monitored simultaneously. sLT was defined as the first steep increase in lactate levels from baseline and was evaluated by three independent investigators. The primary outcome measures were a correlation coefficient of 0.6 or greater between sLT and VT, the similarities as assessed by the Bland–Altman analysis, and the standard deviation of the difference between sLT and VT within 15 W.Results Among the 50 patients, a correlation coefficient of 0.651 (95% confidence interval, 0.391–0.815) was achieved in 32 cases. The difference between sLT and VT was −4.9±15.0 W, and no comparative error was noted in the Bland–Altman plot. No device-related adverse events were reported among the registered patients.Conclusions Our sweat lactate sensor provides a safe and accurate means of detecting VT in patients with HF in a clinical setting, thereby offering valuable additional information for treatment.Successful real-time and continuous monitoring of sweat lactate levels with this experimental device during progressive exercise testing in patients with NYHA class I and II HF.sLT determined by sweat lactate monitoring correlated strongly with VT, suggesting that VT can be detected with sufficient clinical accuracy.Patients with intermediate sweat rates are good candidates for determining sLT.Given the difficulties presented by the current methods for determining VT, the monitoring of lactate values in sweat by our sensors could be helpful for improving VT detection.Our sweat lactate sensor provides a safe and accurate means of detecting ventilatory threshold (VT) in patients with heart failure in a clinical setting.A correlation coefficient of 0.651 (95% confidence interval, 0.391–0.815) was achieved with −4.9±15.0 W as the difference between the lactate threshold in sweat and VT and no comparative error.No device-related adverse events were reported among the registered patients.Competing Interest StatementYoshinori KasumataClinical TrialjRCT2032220057Funding StatementThis study was funded by JST (grant number JPMJPF2101) and Grace Imaging, Inc. Grace Imaging Inc. was not involved in the data analysis or manuscript writing.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board of the Keio University School of Medicine (DA21-006)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCIconfidence intervalHFheart failure;ICCinterclass correlation coefficient;NYHANew York Heart Association;SDstandard deviation;sLTlactate threshold in sweat;VCO2carbon dioxide generation;VEventilation output;VO2oxygen uptake;VTventilator threshold